Tisdag 8 September | 20:57:40 Europe / Stockholm
Est. tid*
2027-06-10 07:15 Bokslutskommuniké 2027
2027-03-04 07:15 Kvartalsrapport 2027-Q3
2026-12-03 07:15 Kvartalsrapport 2027-Q2
2026-09-09 N/A X-dag ordinarie utdelning INTEG B 0.00 SEK
2026-09-03 - Kvartalsrapport 2027-Q1
2026-06-04 - Bokslutskommuniké 2026
2026-03-05 - Kvartalsrapport 2026-Q3
2025-11-21 - Kvartalsrapport 2026-Q2
2025-11-10 - Extra Bolagsstämma 2025
2025-10-29 - Årsstämma
2025-09-25 - X-dag ordinarie utdelning INTEG B 0.00 SEK
2025-09-01 - Kvartalsrapport 2026-Q1
2025-06-03 - Bokslutskommuniké 2025
2025-03-03 - Kvartalsrapport 2025-Q3
2024-12-04 - Kvartalsrapport 2025-Q2
2024-09-26 - X-dag ordinarie utdelning INTEG B 0.00 SEK
2024-09-25 - Årsstämma
2024-08-29 - Kvartalsrapport 2025-Q1
2024-05-30 - Bokslutskommuniké 2024
2024-02-29 - Kvartalsrapport 2024-Q3
2023-12-04 - Kvartalsrapport 2024-Q2
2023-10-04 - X-dag ordinarie utdelning INTEG B 0.00 SEK
2023-09-27 - Årsstämma
2023-08-31 - Kvartalsrapport 2024-Q1
2023-06-08 - Bokslutskommuniké 2023
2023-03-01 - Kvartalsrapport 2023-Q3
2022-12-01 - Kvartalsrapport 2023-Q2
2022-10-03 - X-dag ordinarie utdelning INTEG B 0.00 SEK
2022-09-28 - Årsstämma
2022-08-31 - Kvartalsrapport 2023-Q1
2022-06-10 - Bokslutskommuniké 2022
2022-03-02 - Kvartalsrapport 2022-Q3
2021-12-02 - Kvartalsrapport 2022-Q2
2021-09-09 - X-dag ordinarie utdelning INTEG B 0.00 SEK
2021-09-02 - Kvartalsrapport 2022-Q1
2021-05-31 - Bokslutskommuniké 2021
2021-03-03 - Kvartalsrapport 2021-Q3
2020-12-02 - Kvartalsrapport 2021-Q2
2020-09-30 - Årsstämma
2020-09-09 - X-dag ordinarie utdelning INTEG B 0.00 SEK
2020-08-24 - Kvartalsrapport 2021-Q1
2020-06-08 - Bokslutskommuniké 2020
2020-04-20 - Extra Bolagsstämma 2020
2020-03-02 - Kvartalsrapport 2020-Q3
2019-12-02 - Kvartalsrapport 2020-Q2
2019-09-30 - Årsstämma
2019-09-25 - X-dag ordinarie utdelning INTEG B 0.00 SEK
2019-09-02 - Kvartalsrapport 2020-Q1
2019-06-10 - Bokslutskommuniké 2019
2019-03-04 - Kvartalsrapport 2019-Q3
2018-12-17 - Kvartalsrapport 2019-Q2
2018-09-25 - X-dag ordinarie utdelning INTEG B 0.00 SEK
2018-09-24 - Årsstämma
2018-09-24 - Kvartalsrapport 2019-Q1
2018-06-25 - Bokslutskommuniké 2018
2018-03-26 - Kvartalsrapport 2018-Q3
2017-12-18 - Kvartalsrapport 2018-Q2
2017-09-25 - Årsstämma
2017-09-25 - Kvartalsrapport 2018-Q1
2017-06-30 - Bokslutskommuniké 2017
LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Integrum är verksamt inom medicinteknik. Bolaget utvecklar system för skelettförankrade proteser baserat på det framtagna OPRA-implantatsystemet, som senare vidaresäljs till sjukhus världen över. Implantatet sätts på patientens ben med hjälp utav titanskruvar och antas förbättra livet för en stor del patienter med amputation. Bolaget grundades 1998 och har sitt huvudkontor i Mölndal.

Analysera bolaget i Börsdata!

All ägardata du vill ha finns i Holdings!

Integrum welcomes the Ukrainian Cabinet of Ministers’ decision to introduce a state-funded pilot program for osseointegration

2026-09-08 16:00:00

Mölndal, Sweden, September 8, 2026 — Integrum AB (publ) (Nasdaq First North Growth Market: INTEG B) was informed today that the Cabinet of Ministers of Ukraine has decided to introduce a state-funded pilot program for bone-anchored prostheses. Integrum’s OPRA® Implant System has already been used in over 100 procedures in Ukraine since 2023, and the company has an established clinical presence in the country. The pilot program will run over a two-year period and will be led by Ukraine’s Ministry of Health (MOZ) and the National Health Service of Ukraine (NSZU).

As part of the pilot program, healthcare institutions will receive market-based compensation for the first cohort of 25 patients treated in 2026, in addition to the existing state guarantee reimbursements that already cover the surgical procedure and inpatient rehabilitation. Eligible patients are those with short or deformed transfemoral or transhumeral amputation stumps for whom conventional socket prostheses are not suitable, reflecting the long-term, evidence-based follow-up standard that Integrum has advocated internationally.

The company has established Centers of Excellence in Kyiv and Cherkasy. Dr. Rickard Brånemark has been central to building the company’s presence in the country and continues to support the clinical training of the country’s surgeons. In April 2026, the company recruited a Business Development lead to coordinate its operations in the country. The pilot program has the potential to expand Integrum’s addressable market and contribute to a broader recognition of osseointegration as an established treatment method.

“This decision is highly significant for amputees in Ukraine who, for various reasons, cannot use conventional socket prostheses. Osseointegration offers them the possibility of a functional, bone-anchored prosthesis and a path back to a more active life. The fact that the Ukrainian state has now chosen to fund the pilot program demonstrates strong confidence in the clinical experience built up through the significant number of OPRA procedures already performed in the country, and we look forward to continuing to support Ukrainian hospitals and surgeons in building capacity and expertise in this field,” says Dr. Rickard Brånemark, Chief Medical and Scientific Officer at Integrum.

The Ukrainian authorities announced the decision on September 7, 2026, in Resolution 1095.